Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement

NCT02365415 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Unable to enroll appropriate patients

Conditions

Peripheral Pulmonary Stenosis
In-stent Stenosis

Interventions

DRUG: Sirolimus

Sponsor

Boston Children's Hospital